Bank of New York Mellon Corp Purchases 584,527 Shares of Zoetis Inc. $ZTS

Bank of New York Mellon Corp increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 15.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,305,441 shares of the company’s stock after acquiring an additional 584,527 shares during the period. Bank of New York Mellon Corp’s holdings in Zoetis were worth $541,711,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. RFG Advisory LLC grew its position in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares during the last quarter. YANKCOM Partnership grew its position in Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after acquiring an additional 81 shares during the last quarter. Beese Fulmer Investment Management Inc. lifted its holdings in Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after buying an additional 85 shares during the period. Quest 10 Wealth Builders Inc. lifted its holdings in Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after buying an additional 86 shares during the period. Finally, Financial Engines Advisors L.L.C. lifted its holdings in Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 11,650 shares of company stock valued at $886,384 in the last three months. Corporate insiders own 0.22% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ZTS. BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Stifel Nicolaus cut their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Some market commentary says Zoetis could still be a value opportunity, with one analysis describing the stock as a potential deep-value play with significant upside if the business stabilizes.
• Neutral Sentiment: Zoetis presented at the William Blair Growth Stock Conference, but no major new operating update from that event was highlighted in the headlines provided.
• Negative Sentiment: Multiple law firms announced or reminded investors about a class-action lawsuit alleging securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, with several notices urging shareholders to seek lead-plaintiff status by July 27, 2026. These repeated legal alerts can weigh on the stock. Article Title
• Negative Sentiment: One article said Zoetis has underperformed its industry peers over the past year, reinforcing concerns about recent relative stock performance.
• Negative Sentiment: Investor notices from Robbins Geller, Levi & Korsinsky, the Schall Law Firm, Howard G. Smith, Bernstein Liebhard, The Gross Law Firm, DJS Law Group, and others all highlighted the ongoing lawsuit, increasing headline risk for ZTS.

Zoetis Stock Up 1.5%

Shares of NYSE:ZTS opened at $77.51 on Thursday. The company has a market capitalization of $32.49 billion, a price-to-earnings ratio of 12.85, a P/E/G ratio of 1.25 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The business’s 50-day moving average is $101.99 and its 200-day moving average is $116.09. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $171.52.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.